Karthik Nath1, Vibooshini Ganeshalingam2, Barbara Ewart3, Elizabeth Heyer3, Kerrianne Watt4, Andrew Birchley3, John Casey3, Hock Choong Lai3, Edward Morris3, Georgina Hodges3. 1. Department of Haematology and Bone Marrow Transplantation, Townsville Hospital, 100 Angus Smith Drive, Douglas, Townsville, Queensland, 4814, Australia. karthik.d.nath@gmail.com. 2. College of Medicine and Dentistry, James Cook University, Townsville, Australia. 3. Department of Haematology and Bone Marrow Transplantation, Townsville Hospital, 100 Angus Smith Drive, Douglas, Townsville, Queensland, 4814, Australia. 4. College of Public Health, Medical and Vet Sciences, James Cook University, Townsville, Australia.
Abstract
PURPOSE: The aim of this descriptive study was to assess the prevalence of vitamin D deficiency in patients on active therapy for multiple myeloma in a tropical climate. We also tested for the association of vitamin D status on clinical outcomes. METHODS: This was a single centre, observational study performed in Townsville, Australia, which has a sunlight heavy, tropical climate. Patients on active therapy for multiple myeloma underwent testing of serum 25-hydroxyvitamin D (25(OH)D). Information on disease stage, skeletal morbidity and symptoms of peripheral neuropathy were collected from medical records and self-reported patient questionnaires. RESULTS: A total of 41 patients were included. With a median disease duration of 38 months, 27% were found to be vitamin D deficient. Patients with vitamin D deficiency had a higher likelihood of peripheral neuropathy compared with their non-vitamin D counterparts (73% vs. 33%, P = 0.03). Although those with vitamin D deficiency had more skeletal morbidity, this was not statistically significant (73% vs 50%, P = 0.19). Reduced 25(OH) D was associated with a poor performance status (P = 0.003). There was no association between vitamin D status and stage of myeloma. CONCLUSION: There is a relatively high prevalence of vitamin D deficiency in patients with myeloma in our study. This is despite a sunlight heavy, tropical climate. We report an association between vitamin D deficiency and peripheral neuropathy. Prospective interventional trials are required to further assess this.
PURPOSE: The aim of this descriptive study was to assess the prevalence of vitamin Ddeficiency in patients on active therapy for multiple myeloma in a tropical climate. We also tested for the association of vitamin D status on clinical outcomes. METHODS: This was a single centre, observational study performed in Townsville, Australia, which has a sunlight heavy, tropical climate. Patients on active therapy for multiple myeloma underwent testing of serum 25-hydroxyvitamin D (25(OH)D). Information on disease stage, skeletal morbidity and symptoms of peripheral neuropathy were collected from medical records and self-reported patient questionnaires. RESULTS: A total of 41 patients were included. With a median disease duration of 38 months, 27% were found to be vitamin D deficient. Patients with vitamin Ddeficiency had a higher likelihood of peripheral neuropathy compared with their non-vitamin D counterparts (73% vs. 33%, P = 0.03). Although those with vitamin Ddeficiency had more skeletal morbidity, this was not statistically significant (73% vs 50%, P = 0.19). Reduced 25(OH) D was associated with a poor performance status (P = 0.003). There was no association between vitamin D status and stage of myeloma. CONCLUSION: There is a relatively high prevalence of vitamin Ddeficiency in patients with myeloma in our study. This is despite a sunlight heavy, tropical climate. We report an association between vitamin Ddeficiency and peripheral neuropathy. Prospective interventional trials are required to further assess this.
Entities:
Keywords:
Australia; Multiple myeloma; Peripheral neuropathy; Skeletal morbidity; Vitamin D
Authors: James Wang; Kyle A Udd; Aleksandra Vidisheva; Regina A Swift; Tanya M Spektor; Eric Bravin; Emad Ibrahim; Jonathan Treisman; Mohammed Masri; James R Berenson Journal: Support Care Cancer Date: 2016-02-23 Impact factor: 3.603
Authors: Madeleine Nowak; Simone L Harrison; Petra G Buettner; Michael Kimlin; David Porter; Lee Kennedy; Rick Speare Journal: Photochem Photobiol Date: 2011-06-13 Impact factor: 3.421
Authors: Antonio Palumbo; Hervé Avet-Loiseau; Stefania Oliva; Henk M Lokhorst; Hartmut Goldschmidt; Laura Rosinol; Paul Richardson; Simona Caltagirone; Juan José Lahuerta; Thierry Facon; Sara Bringhen; Francesca Gay; Michel Attal; Roberto Passera; Andrew Spencer; Massimo Offidani; Shaji Kumar; Pellegrino Musto; Sagar Lonial; Maria T Petrucci; Robert Z Orlowski; Elena Zamagni; Gareth Morgan; Meletios A Dimopoulos; Brian G M Durie; Kenneth C Anderson; Pieter Sonneveld; Jésus San Miguel; Michele Cavo; S Vincent Rajkumar; Philippe Moreau Journal: J Clin Oncol Date: 2015-08-03 Impact factor: 44.544
Authors: Pieter Sonneveld; Hervé Avet-Loiseau; Sagar Lonial; Saad Usmani; David Siegel; Kenneth C Anderson; Wee-Joo Chng; Philippe Moreau; Michel Attal; Robert A Kyle; Jo Caers; Jens Hillengass; Jesús San Miguel; Niels W C J van de Donk; Hermann Einsele; Joan Bladé; Brian G M Durie; Hartmut Goldschmidt; María-Victoria Mateos; Antonio Palumbo; Robert Orlowski Journal: Blood Date: 2016-03-21 Impact factor: 22.113
Authors: J G Sfeir; M T Drake; B R LaPlant; M J Maurer; B K Link; T J Berndt; T D Shanafelt; J R Cerhan; T M Habermann; A L Feldman; T Witzig Journal: Blood Cancer J Date: 2017-02-03 Impact factor: 11.037
Authors: B E Oortgiesen; J A Kroes; P Scholtens; J Hoogland; P Dannenberg-de Keijzer; C Siemes; F G A Jansman; R E Kibbelaar; N J G M Veeger; M Hoogendoorn; E N van Roon Journal: Support Care Cancer Date: 2021-07-17 Impact factor: 3.603